• First Berlin reiterated a BUY on Northwest Biotherapeutics, kept its 12-month target price at USD 1.
• FY/25 revenue USD 1.4 million; EBIT loss USD 59.9 million; year-end cash USD 3 million, modestly ahead of First Berlin estimates.
• Q1/26 operating loss narrowed to USD 10.9 million; cash outflow USD 12.5 million; cash fell to USD 1.8 million at March 31, 2026.
• Research flagged UK launch preparations for DCVax-L, citing Sawston manufacturing expansion as a shift toward commercial readiness.
• Key catalyst remains a 2026 MHRA decision for DCVax-L in glioblastoma; positive outcome seen enabling NICE talks, first reimbursed launch in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via EQS News (Ref. ID: rc_25910) on May 28, 2026, and is solely responsible for the information contained therein.